The mechanisms of action of antipsychotic drugs: Is atypicality superior in schizophrenia treatment?

Turk Psikiyatri Dergisi

Volumn 18, Issue 4, 2007, Pages

  Anil Yaǧcioǧlu, A Elif ^a  

^a NONE

Author keywords

Antipsychotics; Mechanisms of action; Schizophrenia

Indexed keywords

EID: 38349014454     PISSN: 13002163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Abi-Dargham A, Laruelle M (2005). Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry; 20:15-27.
2. Andersson JL, Nomikos GG, Marcus M et al. (1995) Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectivity in the mesolimbic dopaminergic system. Naunyn Schmiedebergs Arch Pharmacol, 352:374-85.
3. Bakshi VP, Geyer MA (1995) Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine, Psychopharmacology (Berl), 122:198-201.
4. Bakshi VP, Geyer MA (1997) Phencyclidine induced deficits in prepulse inhibition of startle are blocked by prazosin, an alpha-1 noradrenergic antagonist. J Pharmacol Exp Ther, 203: 666-674.
5. Bressan RA, Etlandsson Y,, Jones HM et al. (2003) Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? An in vivo quantitative [1231]epideprideSPET study of amisulpride-treated patients. Am J Psychiatry, 160:1413-20.
6. Burstein ES, MA J, Wong S et al. (2005) Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the dozapine metabolite N-desmethylclozapine as a D2/ D3 partial agonist. J Pharmacol Exp Ther, 315:1278-87.
7. Chiodo LA, Bunney BS (1983). Typical and atypical neuroleptics: differential effects of chronic administration on die activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci, 3:1607-19.
8. Corbett R, Camacho F, Woods AT et al. (1995) Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology (Berl), 120:67-74.
9. Davis JM, Chen N, Glick ID (2003). A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry, 60:553-64.
10. de Paulis T (2001). M-100907 (Aventis). Curr Opin Invest Drugs, 2:123-32.
11. Di Matteo, V, Di Giovanni G, Di Mascio M et al. (1998) Selective blockade of serotonin2C/2B receptors enhances dopamine release in the rat nucleus accumbens. Neuropharmacology, 37:265-72.
12. Duinkerke SJ, Botter PA, Jansen AA et al. (1993) Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial. Br J Psychiatry, 163:451-5.
13. Duncan GE, Miyamoto S, Leipzig JN et al. (2000) Comparison of the effects of clozapine, risperidone, and olanzapine on ketamine-induced alterations in regional brain metabolism. J Pharmacol Exp Ther, 293:8-14.
14. Elman I, Goldstein DS, Eisenhofer G et al. (1999) Mechanism of peripheral noradrenergic stimulation by clozapine. Neuropsychopharmacology, 20:29-34.
15. Farde L, Nordstrom AL, Wiesel FA et al. (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and dozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry, 49:538-44.
16. Geddes J, Freemantle N, Harrison P et al. (2000) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ, 321:1371-6.
17. Hertel P, Fagerquist MV, Svensson TH (1999) Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adtenoceptor blockade. Science, 286:105-7.
18. Hoyer D, Pazos A, Probst A et al. (1986) Serotonin receptors in the human brain. I. Characterization and autoradiographic localization of 5-HT1A recognition sites. Apparent absence of 5-HT1B recognition sites. Brain Res, 376:85-96.
19. Ichikawa J, Ishii H, Bonaccorso S et al. (2001) 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem, 76:1521-31.
20. Ichikawa J, Dai J, O'Laughlin IA et al. (2002) Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology, 26:325-39.
21. Jakab RL, Goldman-Rakic PS (1998) 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc Natl Acad Sci USA, 95:735-40.
22. Jones PB, Barnes TR, Davies L et al. (2006) Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry, 63:1079-87.
23. Kapur S, Zipursky, RB, Remington G (1999) Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry, 156:286-93.
24. Kapur S, Zipursky R, Jones C et al. (2000) Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry, 157:514-20.
25. Kapur S, Seeman P (2000) Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosci, 25:161-6.
26. Kapur S, Seeman P (2001) Does fast dissociation from the dopamine d(2) receptor explain die action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry, 158:360-9.
27. Kapur S, McClelland RA, VanderSpek SC et al. (2002) Increasing D2 affinity results in the loss of clozapine's atypical antipsychotic action. Neuroreport, 13:831-5.
28. la Fougere C, Meisenzahl E, Schmitt G et al. (2005) D2 receptor occupancy during high- and low-dose therapy with the atypical antipsychotic amisulptide: a 123I-iodobenzamide SPECT study. J Nucl Med, 46:1028-33.
29. Leuner K, Muller WE (2006) The complexity of the dopaminergic synapses and their modulation by antipsychotics. Pharmacopsychiatry, 39(Suppl 1):15-20.
30. Lieberman JA, Stroup TS, McEvoy JP et al. (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med, 353:1209-23.
31. Liégeois JF, Ichikawa J, Meltzer HY (2002) 5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Res, 947:157-65.
32. Meltzer HY, Matsubara S, Lee JC (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther, 251:238-46.
33. Meltzer HY, Li Z, Kaneda Y et al. (2003) Serotonin tereptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry, 27:1159-72.
34. Millan MJ, Dekeyne A, Gobert A (1998) Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology, 37:953-5.
35. Miyamoto S, Duncan GE, Marx CE et al. (2005) Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry, 10:79-104.
36. Monkul ES, Akdede BB (2005). Yeni kuşak antipsikotiklerden aripiprazol:Bir gözden geçirme. Klinik Psikofarmakoloji Bülteni, 15:198-203.
37. Natesan S, VanderSpek S, Nobrega J et al. (2005) Contrasting loxapine to its isomer isoloxapine - the critical role of in vivo D2 blockade in determining atypicality. Schizophr Res, 77:189-99.
38. Ninan I, Jardemark KE, Wang RY (2003) Olanzapine and clozapine but not haloperidol reverse subchronic phencyclidine-induced functional hyperactivity of N-methyl-D-aspartate receptors in pyramidal cells of the rat medial prefrontal cortex. Neuropharmacology 2003; 44:462-72.
39. Nocjar C, Roth BL, Pehek EA (2002) Localization of 5-HT(2A) receptors on dopamine cells in subnuclei of the midbrain A10 cell group. Neuroscience, 111:163-76.
40. Nyberg S, Nakashima Y, Nordström AL et al. (1996) Positron emission tomography of in-vivo binding characteristics of atypical antipsychotic drugs. Review of D2 and 5-HT2 receptor occupancy studies and clinical response. Br J Psychiatry, 168(Suppl. 29):40-4.
41. Olney JW, Farber NB (1994) Efficacy of clozapine compared with other antipsychotics in preventing NMDA-antagonist neurotoxicity. J Clin Psychiatry, 55 (Suppl B):43-6.
42. Perrault G, Depoortere R, Morel E et al. (1997) Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther, 280:73-82.
43. Pilowsky LS, Costa DC, Ell PJ et al. (1992) Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia. Lancet, 340:199-202.
44. Pilowsky LS, Mulligan RS, Acton PD et al. (1997) Limbic selectivity of clozapine. Lancet, 350:490-1.
45. Robertson GS, Matsumara H, Fibiger HC (1994) Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther, 271:1058-66.
46. Schmidt AW, Lebel LA, Howard HR Jr et al. (2001) Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol, 425:197-201.
47. Schwieler L, Engberg G, Erhardt S (2004) Clozapine modulates midbrain dopamine neuron firing via interaction with the NMDA receptor complex. Synapse, 52:114-22.
48. Seeman P (2002) Atypical antipsychotics: mechanism of action. Can J Psychiatry, 47:27-38.
49. Shapiro DA, Renock S, Arrington E et al. (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology, 28:1400-11.
50. Stahl SM (2000). Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 2. baskι, Cambridge, Cambridge University Pres: 365.
51. Stahl SM (2004). Symptoms and circuits, part 3: schizophrenia. J Clin Psychiatry, 65:8-9.
52. Stephenson CM, Bigliani V, Jones HM et al. (2WO) Striatal and extra-striatal D(2)/D(3) dopamine receptor occupancy by quetiapine in vivo. [(123)I]-epidepride single photon emission tomography (SPET) study. Br J Psychiatry, 177:408-15.
53. Sur C, Mallorga PJ, Wittmann M et al. (2003) N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc Natl Acad Sci U S A, 100:13674-9.
54. Svensson T (2003) Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality. Prog Neuropsychopbarmacol Biol Psychiatry, 27:1145-58.
55. Tauscher J, Hussain T, Agid O et al. (2004) Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. Am J Psychiatry, 161:1620-5.
56. Trichard C, Paillere-Martinot ML, Attar-Levy D et al. (1998) Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. Am J Psychiatry, 155:505-8.
57. Wadenberg ML, Salmi P, Jimenez P et al. (1996) Enhancement of antipsychotic-like properties of the dopamine D2 receptor antagonist, raclopride, by the additional treatment with the 5-HT2 receptor blocking agent, ritanserin, in the rat. Eur Neuropsychopharmacol, 6:305-10.
58. Wadenberg MG, Browning JL, Young KA et al. (2001) Antagonism at 5-HT(2A) receptors potentiates the effect of haloperidol in a conditioned avoidance response task in tats. Pharmacol Biochem Behav, 68:363-70.
59. Wadenberg ML, Wiker C, Svensson TH (2006) Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive alpha 2 adrenoceptor blockade: experimental evidence. Int J Neuropsychopharmacol: 1-12.
60. Waddington JL, Kapur S, Remington GJ (2003). The neuroscience and clinical psychopharmacology of first- and second-generation antipsychotic drugs. Schizophrenia, 2. baski, SR Hirsch, DR Weinberger (Ed), Oxford. Blackwell Science Ltd: 421-441.
61. Weiner DM, Meltzer HY, Veinbergs I et al. (2004) The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology (Bed), 177:207-16.
62. Willins DL, Deutch AY, Roth BL (1997) Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse, 27:79-82.
63. Wong AH, Van Tol HH (2003) The dopamine D4 receptors and mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry, 27:1091-9.
64. Xiberas Y, Martinot JL, Mallet L et al. (2001) In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia. J Clin Psychopharmacol, 21:207-14.
65. Zhang W, Perry KW, Wong DT et al. (2000) Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology, 23:250-62.